Cutaneous melanoma
Clinical trials for Cutaneous melanoma explained in plain language.
Never miss a new study
Get alerted when new Cutaneous melanoma trials appear
Sign up with your email to follow new studies for Cutaneous melanoma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for High-Risk melanoma: combo therapy aims to prevent recurrence
Disease control Stopped earlyThis study tested whether adding vibostolimab to the standard immunotherapy pembrolizumab can better prevent melanoma from returning after surgery. About 1,600 people with high-risk stage II to IV melanoma took part. The goal was to see if the combination keeps cancer away longer…
Matched conditions: CUTANEOUS MELANOMA
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Experimental combo for Hard-to-Treat cancers shows early promise but study halted
Disease control Stopped earlyThis early-phase trial tested a combination of two oral drugs, mirdametinib and brimarafenib, in 23 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to check safety, find the best dose, and see if the combo could shrink tumors. Th…
Matched conditions: CUTANEOUS MELANOMA
Phase 1/2 • Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Promising melanoma combo trial halted early – only one patient enrolled
Disease control Stopped earlyThis study tested a new drug called acasunlimab, given alone or with pembrolizumab, in people with advanced melanoma that had stopped responding to standard treatments. The trial was terminated early after enrolling only one participant, so no conclusions can be drawn about safet…
Matched conditions: CUTANEOUS MELANOMA
Phase 2 • Sponsor: Genmab • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New drug trial offers hope for Hard-to-Treat cancers
Disease control Stopped earlyThis early-stage study tests a new drug, PF-08046049/SGN-BB228, in people with advanced melanoma and other solid tumors that have spread or stopped responding to standard treatments. The main goal is to check the drug's safety and find the best dose. About 41 participants will ta…
Matched conditions: CUTANEOUS MELANOMA
Phase 1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Super-Fine ultrasound could spare melanoma patients a second surgery
Diagnosis Stopped earlyThis trial investigates whether a new, ultra-high-frequency ultrasound device can accurately measure the depth of skin melanomas before surgery. Currently, doctors must remove the tumor, measure its depth under a microscope, and then often perform a second surgery to remove more …
Matched conditions: CUTANEOUS MELANOMA
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Diagnosis
Last updated Jun 27, 2026 14:00 UTC
-
Can smartphone cameras spot skin cancer as well as a dermatologist?
Diagnosis Stopped earlyThis study tested three portable imaging systems (MoleMapper, Visiomed, and confocal microscopy) to see how well they could detect melanoma compared to a dermatologist's exam. Seventeen people with suspicious moles participated. The goal was to find out if these devices could acc…
Matched conditions: CUTANEOUS MELANOMA
Sponsor: OHSU Knight Cancer Institute • Aim: Diagnosis
Last updated Jun 27, 2026 12:05 UTC